Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease which af- fects the lower and upper motor neurons, which are responsible for voluntary movements. The causes of the disease are unknown, and the disease remains incurable. Due to its heterogeneity, drug development for ALS comprises a great challenge. Cell models obtained from patients’ blood have been used for the experimental procedures carried out on this project. These models recapitulate the TAR-DNA binding protein 43 (TDP-43) abnormalities observed in patient neurons. For this project, the size, concentration and ALS related biomolecules content of extracellular vesicles (EVs) produced by lymphoblastic ALS models and control lymphoblasts have been studied. EVs have been labelled with Quantum Dot nanoparticles (QD). The effects of a casein kinase 1δ (CK-1δ) inhibitor on these EVs have been analyzed.